Gerald F. Joyce Elected to the Institute of Medicine at the National Academy of Sciences
La Jolla, CA, USA, 10 A. M., October 20, 2014 -Gerald F. Joyce, M.D., Ph.D., is elected to the Institute of Medicine (IOM), the US National Academies of Sciences announced following the IOM's 44th annual meeting.¹ Joyce is perhaps best known as one of the inventors of directed evolution technology and, more recently, for creating the first self-replicating RNA enzyme.
"I am honored to join the IOM and look forward to working with my colleagues and health policy makers on tackling the challenges facing our nation's health care system," said Joyce.
Earlier this month Joyce joined Novartis as Director of the Genomics Institute of the Novartis Research Foundation (GNF) in La Jolla, California. GNF, part of the Novartis Institutes for BioMedical Research (NIBR), embraces the complexity of biological systems. GNF researchers use cutting-edge technology--including automation and robotics developed at the institute--to take advantage of emerging large-scale, data-rich fields for drug discovery. With a robust blend of basic science, engineering, and drug discovery research expertise, GNF plays a vital role in NIBR's commitment to change the practice of medicine.
"We are thrilled that Jerry has joined Novartis as the Director of GNF and congratulate him on his election to the Institute of Medicine," said Mark Fishman, President of the Novartis Institutes for BioMedical Research. "He is a pioneering physician scientist whose research is helping us bridge the gap between science and medicine in our mission to discover new medicines."
Prior to joining GNF, Jerry served as Dean of the Faculty at The Scripps Research Institute. He will maintain his faculty position there with the Department of Chemistry. Jerry is a member of the U.S. National Academy of Sciences and the American Academy of Arts and Sciences.
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "potential," "look forward," "commitment," "mission," "will," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.
Novartis Media Relations
Central media line : +41 61 324 2200
Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
Novartis Institutes for BioMedical Research
+41 61 324 8137 (direct)
+41 79 959 6899 (mobile)
For Novartis multimedia content, please visit http://www.
For questions about the site or required registration, please contact: firstname.lastname@example.org.